Mass spectrometry is moving from scientific research to clinical
It is reported that the biotechnology company “Zhongke New Life” recently announced that it has completed a round of financing of nearly 200 million yuan. The leading investors in this round are Luxin Venture Capital and Wuxi Gold Investment. Fang is Guangzhou Fundao Assets. The proceeds from this round of financing will be mainly used for the company’s mass spectrometry platform capacity center and supercomputer center construction, precision medical product development, and expansion of domestic and foreign markets.
Zhongke New Life was founded by the Shanghai Academy of Life Sciences, Chinese Academy of Sciences, and is mainly engaged in the application of mass spectrometry technology.
The so-called mass spectrometry technology is to measure the quality of protein molecules to carry out the identification of protein molecules, the modification of protein molecules and the study of protein molecule interactions. Put into the industry, it is usually used for microbial identification and neonatal genetic disease screening, these two applications have been relatively mature in China. In addition, mass spectrometry technology can also be used for vitamin and blood concentration monitoring and small molecular marker research.
In the mass spectrometry track, the new predecessor of China Science and Technology, formerly known as the Proteome Research and Analysis Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, is regarded as an early entry and was established in 2004.
Zhongke New Life ’s core technical advantage lies in the development of anti-tumor drug screening and target evaluation analysis methods based on parallel reaction monitoring mass spectrometry technology, DIA data collection technology based on mass spectrometry, and the realization of biomedical analysis detection and Online assessment.
In terms of products, the company has established three service platforms for technology services (protein / modification / metabolic research), biomedical characterization confirmation and precision medicine, which is the first to participate in international One of the platforms for liver and plasma projects has obtained CMA measurement certification, D & B certification and ISO9001 quality certification.
In order to improve the security of user data, Zhongke New Life has also established a laboratory information management system with independent intellectual property rights.
Papers and patents are important measures of technical level, users use the company ’s service results Hundreds of papers have been published in high-level SCI journals, including Science, Nature Genetics, Cell Research, Nature Communications, etc. Obtained more than 30 invention patents and professional copyrights.
MS industryIn the middle and upstream oligopolistic instruments, most of them rely on imports. In response to this industry feature, Zhongke New Life has reached a strategic cooperation with international head mass spectrometry manufacturers. The partners include SCIEX, Thermo Fisher Scientific, and Waters.
According to public data, the users of Zhongke New Life have covered more than one thousand pharmaceutical companies, two thousand research institutes and hospitals at home and abroad, and have provided more than one million sample testing and project services.
As the technology matures, mass spectrometry is gradually moving from scientific research to clinical practice. The industry is optimistic about the future market space of mass spectrometry. Clinical mass spectrometry in the United States accounts for 15% of the medical detection market, while China currently has only 1-2%. There are still great opportunities for market expansion. The companies that received financing on the track in 2019 include Rongzhi Biology, Yingsheng Biology, Baichen Diagnostics, Baiqu Biology, etc., of which Rongzhi and Yingsheng’s financing are close to 100 million yuan.